Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirapazamine and TAE in Liver Cancer
NCT02174549Phase 2Recruiting
- Sponsor
- Teclison
- Start
- Sep 2014
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirapazamine in liver cancer, hepatocellular carcinoma (HCC) and Neuroendocrine Neoplasm (NEN), sponsored by Teclison. Primary endpoint: Overall Response Rate at 2 years. Started Sep 2014; status: recruiting.
02
Drugs
tirapazamine
03
Conditions
liver cancerhepatocellular carcinoma (HCC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02174549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174549.